ANVISA Medical Device Regulation Update 2026: Brazil-Chile Regulatory Cooperation

Brazil’s National Health Surveillance Agency (ANVISA) strengthened Latin America’s medical device regulatory collaboration through a technical exchange with Chile’s Institute of Public Health (ISP) in July 2026. The initiative provided insights into Brazil’s medical device regulatory framework, including registration, Good Manufacturing Practice (GMP) certification, inspections, import controls, and post-market surveillance. This cooperation supports regulatory convergence and helps manufacturers better understand evolving medical device requirements across the region.

Key Highlights of ANVISA’s Technical Exchange With Chile’s ISP

From July 6–10, 2026, ANVISA hosted a technical delegation from Chile’s Institute of Public Health (ISP) to promote knowledge sharing and strengthen regulatory cooperation in the medical device sector.

The exchange focused on Brazil’s approach to managing medical devices throughout their entire lifecycle, from company authorization and product approval to ongoing safety monitoring after market entry.

The technical discussions covered important regulatory areas, including:

• Company authorization
• Medical device product registration
• Good Manufacturing Practice (GMP) certification
• Import control processes
• Regulatory inspections
• Post-market surveillance activities

The exchange provided an opportunity for both regulatory authorities to share experiences and strengthen cooperation related to medical device oversight.

Strengthening Regulatory Cooperation in Medical Devices

The collaboration between ANVISA and Chile’s Institute of Public Health highlights the importance of international cooperation among regulatory authorities.

Through technical exchanges, agencies can share regulatory knowledge, experiences, and best practices that contribute to stronger oversight systems for medical devices.

This initiative reflects ANVISA’s commitment to:

• International collaboration
• Regulatory convergence
• Exchange of regulatory best practices

Supporting Stronger Medical Device Oversight in Latin America

The technical exchange between ANVISA and ISP contributes to broader efforts to strengthen medical device regulation throughout Latin America.

By sharing knowledge on regulatory processes across the medical device lifecycle, health authorities can improve understanding of different oversight approaches and promote closer cooperation in the region.

How Medical Device Manufacturers Can Prepare for Regulatory Changes

1. Understand Local Regulatory Requirements

Companies should evaluate ANVISA requirements for device classification, registration pathways, and quality system obligations before entering the Brazilian market.

2. Maintain Strong Quality Management Systems

Compliance with GMP principles and effective quality management processes are essential for successful regulatory approval and continued market access.

3. Monitor Post-Market Obligations

Manufacturers should establish systems for adverse event reporting, product monitoring, and corrective actions after commercialization.

4. Follow Regional Regulatory Developments

Ongoing regulatory cooperation between agencies such as ANVISA and ISP may lead to greater alignment of medical device requirements across Latin America.

Conclusion

ANVISA’s technical exchange with Chile’s Institute of Public Health demonstrates the value of regulatory collaboration in advancing medical device oversight.

The July 2026 visit provided a platform for sharing experiences related to authorization, registration, GMP certification, import controls, inspections, and post-market surveillance. Such initiatives support continued cooperation and the exchange of best regulatory practices among Latin American regulatory authorities.

Learn more about ANVISA Brazil Medical Device Registration and read the ANVISA official publication.